Institutional members access full text with Ovid®

Share this article on:

Efficacy of Trabectedin in Platinum-Sensitive-Relapsed Ovarian Cancer: New Data From the Randomized OVA-301 Study

Colombo, Nicoletta MD

International Journal of Gynecological Cancer: May 2011 - Volume 21 - Issue 10 - pp S12-S16
doi: 10.1097/IGC.0b013e318217b321
Review Article

The results of the OVA-301 study show that trabectedin in combination with pegylated liposomal doxorubicin (PLD) results in improved progression-free survival and response rate in patients with advanced ovarian cancer. The trial has also demonstrated a trend toward improvement in overall survival. A subgroup analysis indicates that in the subset of patients with platinum-free interval (PFI) of 6 to 12 months, the combined treatment resulted in a 6-month improvement in overall survival. Furthermore, in the patients who have received third-line treatment with a platinum agent, it was found that the survival was better in those who had received trabectedin and PLD. These results suggest that prolonging the PFI by a nonplatinum-effective regimen improves the outcome with subsequent, third-line platinum treatment. This strategy may also have positive effects in treatment tolerability, as it allows extra time to recover from platinum-induced toxicities. This hypothesis is currently been tested in the INOVATYON (INternational OVArian Cancer Patients Trial With YONdelis) phase III study.

Istituto Europeo di Oncologia, Milan, Italy.

Received February 25, 2011.

Accepted for publication February 27, 2011.

Address correspondence and reprint requests to Nicoletta Colombo, MD, Istituto Europeo di Oncologia, Milan, Italy. E-mail: nicoletta.colombo@ieo.it.

Disclosure: Editorial assistance for the preparation of this manuscript was funded by PharmarMar.

Copyright © 2011 by IGCS and ESGO